Amryt Pharma (AMYT) Share Price, News & Analysis

Company Overview

Amryt Pharma plc, a commercial-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate, which is in Phase 3 EASE trial for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 that is in preclinical stage for the treatment of patients with recessive dystrophic EB, a subset of EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 90,726 shs
• Average Volume: 469,552 shs
• Market Capitalization: £457.11 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: LON:AMYT
• Previous Symbol: LON:FAST
• CIK: N/A
• Web: www.amrytpharma.com
• Phone: +44-20-34155730
• Fax: N/A
• Employees: 290
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 66.05
• Current Ratio: 1.80
• Quick Ratio: 1.14

Sales & Book Value

• Annual Sales: £210.24 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 3.68
• Book Value: GBX 96.60 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 319,657,000
• Free Float: N/A
• Market Cap: £457.11 million
• Optionable: Not Optionable
• Beta: N/A